FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAF V600E mutation

 

Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply